To The Moon

Novo Nordisk (NVO, Financial) just scored a game-changing FDA approval for Ozempic, expanding its use beyond diabetes to tackle chronic kidney disease and cardiovascular risks. The move solidifies Oze

"Startups OpenAI and Anthropic have been battling Google, Meta and others in developing large, multimodal and small language foundation models.Further, DeepSeek reportedly spent only $5.6 million over two months to develop its latest AI model, noted economist Ed Yardeni in a report.Meanwhile, DeepSeek's success could weigh on U.S. earnings reports, Yardeni said, amid enormous capital spending increases by Google, Meta, Microsoft and others. Microsoft is the biggest investor in OpenAI."This migh

Clothing brands are among the businesses benefiting from the GLP-1 boom as users treat their slimmer selves. Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.But slimming down comes with a price, albeit one that the 39-year-old Chicago resident said she's more than willing to pay. Specifically, Allen has had to buy new clothes - some $5,000 worth - to fit her trimmer frame. Plus, there's a psychological component to her recent fashion fervor."I look better, so I want to reward my body," Allen told MarketWatch.Some clothing brands could be among the winners, as research firms that track consumer spending are already finding. For example, Impact Analytics found that sales for smaller-sized women's shirts increased by 12.1%, based on a survey of New York retailers. Perhaps not surprisingly, sales for larger sizes declined. But experts generally say that when people ar

COPENHAGEN, Jan 24 - Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.Shares jumped on the release and traded up 10% in premarket trading.Amycretin targets the same gut hormone that Wegovy mimics, known as GLP-1, but also a pancreas hormone called amylin that affects hunger."The results seen in the trial support the weight

Nvidia $(NVDA)$ was the most remarkable technology story of 2024 - both in terms of its products and impact on the stock market. The company's strategic advancements in data-center GPUs and networking

The first shipments of racks equipped with Nvidia's newest chips, Blackwell, have been plagued by overheating as well as glitches involving the way the chips connect to one another, according to three people working at suppliers and two customers that have dealt with the issues, the Information reported.Nvidia shares extended losses to about 4% in premarket trading.

Nvidia said Friday it has created a blueprint for a generative AI workflow designed to support online and in-store shopping.Using the Nvidia AI Enterprise and Omniverse platforms, developers will be able to create AI-powered digital assistants with features including multimodal and multi-query capabilities, reasoning capabilities for humanlike interactions, and simulation tools to help customers visualize how products would look on them or in their spaces, the company said.Nvidia's NeMo microservices within the blueprint can understand text and image prompts, search for multiple items at once, handle complex tasks like creating a travel wardrobe, and answer questions from customers, the company added.The Nvidia AI Blueprint for retail shopping assistants is currently available in early access, with SoftServe, Dell Technologies and World Wide Technology among the users, Nvidia said.Price: 135.05, Change: -5.06, Percent Change: -3.61